Bad year at Celgene? Forget about it. CEO Mark Alles nabbed a big raise as compensation gyrated to $16.2M
By all accounts, 2018 was a grim year for Celgene. Just months after it $CELG was forced to scrap its $710 million drug
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
